|

Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure

RECRUITINGPhase 4Sponsored by Evi Liliek Wulandari
Actively Recruiting
PhasePhase 4
SponsorEvi Liliek Wulandari
Started2025-06-30
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07259512

Summary

This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Female or Male with age \>18 years old
* Patients with a diagnosis of CKD stage 3-5 non-dialysis with low ejection fraction heart failure (ejection fraction \< 40%)

Exclusion Criteria:

* Receiving hemodialysis therapy
* History of intolerance to ACE inhibitors
* Refractory hyperkalemia
* Pregnancy
* History of angioedema to ACE inhibitors
* Receiving sacubitril-valsartan therapy
* Receiving ARB therapy
* Hypotension with blood pressure \<90/60, or patients in shock.

Conditions3

Chronic Kidney DiseaseHeart DiseaseHeart Failure With Reduced Ejection Fraction (HFrEF)

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.